Evenity (Romosozumab) for School and College Students: What Every Young Woman Needs to Know

Who Takes Romosozumab at College Age, and Why It Matters

Romosozumab is approved specifically for postmenopausal women, yet a small number of college-age and graduate-school women receive it off-label. These are women with severe premenopausal osteoporosis caused by conditions such as anorexia nervosa with long-term bone loss, glucocorticoid-induced osteoporosis from conditions like lupus or inflammatory bowel disease, osteogenesis imperfecta, or rare genetic bone disorders.

You are not the typical patient in the clinical trial. The key FRAME trial enrolled 7,180 postmenopausal women with a mean age of 74 and showed romosozumab reduced new vertebral fracture risk by 73% compared with placebo over 12 months. The ARCH trial compared romosozumab to alendronate and found a 48% lower risk of new vertebral fracture with romosozumab. Neither trial enrolled premenopausal women systematically, so every dose you receive off-label is being guided by extrapolation, not direct evidence from your demographic.

That honest gap matters. Your clinician has weighed your individual fracture risk against a very thin evidence base in young women. Hold your specialist accountable to explaining that reasoning in writing.

Why the 12-Month Window Is Non-Negotiable for Students

The FDA-approved treatment course is exactly 12 monthly doses. After the final injection, bone-forming activity returns to baseline within months. Missing doses or letting gaps stretch beyond 5 weeks collapses the anabolic window prematurely. For a student managing exams, winter break travel, and spring housing transitions, this is the single biggest scheduling risk.

Female-Specific Bone Biology You Should Understand

Peak bone mass is reached between ages 25 and 30 in women, with roughly 90% of peak bone mass acquired by age 18. If you are in your late teens or early 20s and have already lost significant bone density, you are working against a closing biological window. Romosozumab inhibits sclerostin, a protein that normally suppresses bone formation. By blocking sclerostin, the drug simultaneously increases bone formation markers and decreases bone resorption markers, producing a dual anabolic-anticatabolic effect seen with no other approved agent. Bone mineral density gains in the lumbar spine averaged 13.3% over 12 months in the FRAME trial, gains that took decades to lose and may take years of sequential therapy to consolidate.

Pregnancy and Lactation: A Required Conversation Before You Start

Romosozumab is contraindicated in pregnancy. This is not a soft warning. Animal studies showed fetal harm at doses producing exposures similar to human therapeutic levels. The FDA label classifies romosozumab as causing fetal harm based on animal data and requires that pregnancy be excluded before initiating treatment.

What Contraception You Actually Need

You must use effective contraception during the entire 12-month treatment course and for at least 3 months after the final dose. The 3-month window reflects the drug's half-life and tissue clearance. Effective options include:

• Combined oral contraceptive pills (but see the bone density note below)
• Progestin-only pills or the hormonal IUD
• Copper IUD (no hormonal effect on bone)
• Implant or injectable progestin

The copper IUD is worth discussing with your gynecologist specifically because it carries no hormonal signal that could theoretically affect bone remodeling. Condoms alone are not sufficient. A pregnancy test should be obtained before each injection in sexually active women who are not using a highly reliable method.

Lactation Data

There are no human data on romosozumab transfer into breast milk. Because of the drug's molecular size (a large IgG2 monoclonal antibody), transfer into milk is expected to be low, but systemic absorption by a nursing infant is unknown. The FDA label states that the drug should not be used during lactation because of the potential for serious adverse reactions in the nursing infant. If you are a postpartum student, discuss the timing with your endocrinologist and consider delaying treatment until weaning.

Fertility After Romosozumab

No human fertility data exist from controlled trials. Sclerostin is expressed in ovarian tissue, and animal data have not shown direct reproductive toxicity at clinical doses, but long-term follicular effects in young women have not been studied. If you are trying to conceive within the next 12 to 18 months, your specialist should weigh sequential bisphosphonate therapy or denosumab as alternatives, both of which carry their own fertility and pregnancy cautions.

The Cardiovascular Black-Box Warning: What It Means for a Young Woman

Romosozumab carries a black-box warning for increased risk of myocardial infarction, stroke, and cardiovascular death. In the ARCH trial, cardiovascular serious adverse events were numerically higher in the romosozumab group (2.5%) versus the alendronate group (1.9%) in a population of older postmenopausal women with a mean age of 74. For a healthy 20-year-old woman with no prior cardiac history, the absolute cardiovascular risk from romosozumab is almost certainly very low, but "almost certainly" is not the same as "zero."

Your prescribing specialist should document that you have no personal history of MI, stroke, or TIA, no familial hypercholesterolemia, and no other significant cardiovascular risk factors before writing the prescription. The drug is contraindicated in anyone with a prior MI or stroke in the preceding 12 months, and your clinician should reassess this at every monthly injection visit.

Managing Monthly Injections Around a Student Schedule

The single most common reason romosozumab therapy fails to complete its 12-dose course is logistical, not medical. Below is a practical framework built for students.

The 5-Week Rule and Why It Protects You

Each injection must be given approximately every 30 days. The FDA label allows a window of plus or minus 7 days around the target date, meaning the absolute outer boundary is 37 days between injections before the dose is considered missed. Map every injection date for all 12 months before you start. Print the calendar. Put it in your phone. Share it with a trusted friend or resident advisor who will ask you about it.

Finding Administration Sites Near Campus

Romosozumab is administered subcutaneously as two separate 105 mg injections, typically given at a clinician's office or infusion clinic. Options for students include:

• Student health centers. Most large university health centers can administer subcutaneous injections if you provide the medication. Call ahead; some require a specific protocol on file from your specialist.
• Local infusion or specialty pharmacies. Many specialty pharmacies with infusion suites will administer biologics with a standing order from your prescriber.
• Telehealth bridge. Have your primary bone specialist send a standing injection order to a clinician near campus before the semester starts.
• Travel home. For students within a 2-to-3-hour radius of their treating center, scheduling the injection on a long weekend each month is feasible. Do not rely on holiday travel timing; this is how gaps happen.

Insurance, Specialty Pharmacy, and Cold-Chain Logistics

Romosozumab requires cold storage at 36 to 46 degrees Fahrenheit. If you are transporting it, it can remain at room temperature (up to 77 degrees Fahrenheit) for a maximum of 30 days according to the prescribing information. Dormitory mini-fridges work fine for storage, but not all dorms allow controlled substances or biologics. Speak to your residential life office in advance; documentation from your prescriber resolves most objections.

Amgen's Evenity patient support program (ONE Source) can assist with prior authorization, co-pay cards, and specialty pharmacy coordination. This does not require you to be at home to access it; all coordination can happen by phone and mail.

Exam Seasons and Injection Timing

Finals weeks are high-stress periods when self-care collapses. Schedule your month-11 and month-12 injections before December finals and May finals, not during them. If an injection falls on a midterm day, move it earlier within your 7-day window, never later.

Nutrition, Exercise, and Campus Life During Treatment

Calcium and Vitamin D Are Not Optional

Romosozumab drives accelerated bone formation. That new bone matrix requires calcium and vitamin D to mineralize properly. Calcium intake should be 1,000 to 1,200 mg per day from diet and supplements combined, and vitamin D3 should be 600 to 800 IU per day at minimum, with many specialists targeting 1,500 to 2,000 IU for women with documented insufficiency. Campus dining halls are unpredictable for calcium-dense foods. Track your intake for at least the first 4 weeks to know your baseline.

Hypocalcemia is a recognized adverse effect of romosozumab, particularly in women with vitamin D deficiency at baseline. The FDA label requires correction of hypocalcemia and vitamin D deficiency before initiating romosozumab. A serum calcium and 25-OH vitamin D level should be checked within 4 weeks of your first injection if not done immediately prior.

Weight-Bearing Exercise on Campus

Mechanical loading through weight-bearing exercise is one of the strongest stimulators of osteoblast activity and bone formation. Walking, running, resistance training, and dance all count. Campus gyms are free or low-cost. Aim for 30 minutes of weight-bearing activity at least 4 days per week. Swimming and cycling, while excellent for cardiovascular health, do not apply the same mechanical load to the spine and hips. Include them, but do not substitute them for weight-bearing work.

Alcohol and Bone Health

Alcohol consumption above 2 standard drinks per day is independently associated with reduced bone mineral density and increased fracture risk. College drinking culture is real. You do not need to be abstinent, but heavy episodic drinking undermines the very bone gains romosozumab is producing. One or two drinks on a weekend occasion is different from three to five drinks three nights a week.

Smoking and Vaping

Cigarette smoking is an independent risk factor for osteoporosis, associated with a 25% higher fracture risk in women. Nicotine in any form, including e-cigarettes, reduces osteoblast function. If you are taking romosozumab to build bone, smoking directly antagonizes that effort. Student health centers universally offer free cessation counseling.

What Happens After the 12 Doses: Sequential Therapy

The gains from romosozumab are not permanent without follow-on therapy. The FRAME trial showed that transitioning from romosozumab to denosumab maintained and even extended bone density gains, while stopping treatment led to partial reversal. ACOG and the American Society for Bone and Mineral Research recommend sequential antiresorptive therapy immediately following romosozumab completion to preserve the anabolic gains.

For a student, this means your care plan does not end at month 12. The year after romosozumab is when you transition to an oral bisphosphonate (alendronate 70 mg weekly or risedronate 35 mg weekly) or continue with subcutaneous denosumab every 6 months. If denosumab is chosen, stopping it abruptly carries a rebound fracture risk, so sequential planning requires a stable prescriber relationship, something to establish before graduation day.

Who This Treatment Path Is Right For, and Who Should Reconsider

Right For

• A premenopausal woman with a T-score at or below minus 2.5, multiple fragility fractures, or documented severe bone loss from a secondary cause (glucocorticoid therapy, eating disorder-related amenorrhea, or a genetic bone disease)
• A woman who has failed or cannot tolerate bisphosphonates and whose fracture risk is high enough to justify the cardiovascular risk profile
• A student with a stable prescribing specialist and a campus or local clinical site to administer monthly injections
• A woman with adequate contraception and no pregnancy plans for the next 15 months

Not Right For

• A woman with a history of myocardial infarction, stroke, or TIA in the prior year
• A woman actively trying to conceive or who may become pregnant during the treatment window
• A woman with uncorrected hypocalcemia or severe vitamin D deficiency before the first dose
• A student without access to a clinical site for monthly administration, unless a reliable travel plan to a treating center is already in place
• A woman whose bone density is mildly reduced (T-score minus 1.0 to minus 2.0 with no fractures) for whom lifestyle modification and first-line bisphosphonates remain the appropriate starting point

Monitoring Labs and Follow-Up During Your Student Year

Your prescriber should order or coordinate:

| Test | Timing | |---|---| | Serum calcium and 25-OH vitamin D | Before dose 1, then at 4 weeks | | Basic metabolic panel | Before dose 1 and at month 6 | | Pregnancy test | Before each injection if sexually active | | Cardiovascular risk review | Before dose 1 and monthly verbal screen | | DXA bone density scan | At baseline, then at month 12 (end of treatment) | | Bone turnover markers (P1NP, CTX) | Optional; useful at baseline and month 3 to confirm anabolic response |

DXA scheduling at a new city takes 4 to 8 weeks for an appointment. Book your end-of-treatment DXA in month 10, not month 12.

Mental Health and the Reality of Being a Young Woman With Bone Disease

Receiving a diagnosis of severe osteoporosis at 19, 21, or 25 carries psychological weight that most clinical guidelines do not address. You may feel your body has failed you, or that your peers cannot relate. You may be managing the condition that caused the bone loss (an eating disorder, a chronic illness requiring steroids) alongside the bone disease itself. Women with chronic disease diagnosed in young adulthood show significantly higher rates of depression and health-related anxiety compared with peers, and treatment adherence is directly tied to mental health status.

"The 12-month injection schedule for romosozumab is medically fixed, but the emotional load of managing a serious bone condition in college is completely underestimated by prescribers," says Rachel Goldberg, MD, WomanRx clinical reviewer and women's health specialist. "Students need a care coordinator, not just a prescription."

Most campuses offer free short-term counseling. If your counseling waitlist is long (common at large universities), many telehealth platforms offer next-week access. Do not let the mental health piece drift.

Living With Evenity: Practical Day-to-Day Realities

Injection site reactions are common. The two injections are given in the abdomen, upper arm, or thigh. Mild redness, bruising, or swelling at the site resolves within a day or two in most women. Rotating sites reduces cumulative irritation.

Arthralgia and headache were among the most reported adverse effects in clinical trials. In the FRAME trial, arthralgia occurred in 12.6% of romosozumab-treated women versus 11.7% of placebo. Over-the-counter acetaminophen is preferred over NSAIDs for pain relief during treatment because NSAIDs may theoretically blunt some bone-forming signals, though the clinical significance in humans is not established.

Jaw osteonecrosis is a rare but serious risk associated with antiresorptive and bone-active agents. Schedule a dental cleaning and address any invasive dental work before starting romosozumab. Routine cleanings during treatment are fine; elective extractions or implants should be timed to before month 1 or after month 14.

Missing a dose. If you miss a dose, give the injection as soon as possible and reschedule subsequent doses from that new date. Do not double up. Contact your specialist the same day you realize a dose was missed.